"Adapt. Endure. Advance."
Fighting for your future
CNS-X (Central Nervous System Strain X) is a parasitic virus that targets the brain when it enters the body. Founded by Geraldine Aven in 2002, Greymatter Inc. has been a pioneer in CNS-X research. Although the origins of the virus are unclear, we have manufactured the first experimental CNS-X vaccine, NX-block, that could prevent infection and immunize the patient.
About Us
Once a quiet biomedical startup, we pivoted into a front line coalition—equal parts field hospital, data‑lab, and mobile engineering corps. Today, Greymatter operates out of repurposed observation domes ringing the quarantine zone, where we perform critical research and operations for the sake of humanity.
Our Mission
Since 2002, our researchers, scientists, and doctors have been searching for a permanent cure to the CNS-X virus. Today, our team is inches away from manufacturing the first batch of Neurovaxin, a vaccine that will both prevent and cure CNS-X. Your support for Greymatter Inc. is leading to a healthier, cleaner, and better future.